Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 18/20 | 0.49 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1425283 | 0.86 | KCNN4 (0.45) | KCNN4 | |
| SCHEMBL2358883 | 0.83 | KCNN4 (0.46) | KCNN4ALDH1A1 | |
| SCHEMBL1426001 | 0.81 | KCNN4 (0.42) | KCNN4ALDH1A1 | |
| SCHEMBL985261 | 0.80 | KCNN4 (0.55) | KCNN4 | |
| SCHEMBL987916 | 0.78 | KCNN4 (0.52) | KCNN4ALDH1A1 | |
| SCHEMBL12810736 | 0.77 | LRRK2 (0.45) | KCNN4ALDH1A1 | |
| SCHEMBL12539009 | 0.76 | FYN (0.35) | KCNN4ALDH1A1 | |
| SCHEMBL2356773 | 0.76 | KCNN4 (0.42) | KCNN4ALDH1A1 | |
| SCHEMBL1425926 | 0.75 | PDGFRB (0.39) | KCNN4 | |
| SCHEMBL27918674 | 0.74 | FYN (0.44) | KCNN4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| EP-2350045-A1 | C-MET PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010048131-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | KCNN4 4066/4885AKT1 52/4885ALDH1A1 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.